← All trials
NCT02955771
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2017
- Primary completion
- Dec 26, 2018
- Completion date
- Dec 26, 2018
- First posted
- Nov 4, 2016
- Last posted
- Jul 17, 2019
- Enrollment
- 7
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Zhangjiang Biotechnology Limited CompanyLead sponsor
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.